163 results about "Local injection" patented technology

The invention provides a branched transport polymer characterized as having at least 10 amino acids and a ratio of histidine to non-histidine amino acids greater than 1.5, said branched transport polymer comprising one or more backbones, one or more terminal branches, and optionally, one or more non-terminal branches. The branched transport polymer may be associated with a pharmaceutical agent to form a pharmaceutical agent delivery composition useful for in vivo therapies based on local injection.

A renal flow system injects a volume of fluid agent into a location within an abdominal aorta in a manner that flows bi-laterally into each of two renal arteries via their respectively spaced ostia along the abdominal aorta wall. A local injection assembly includes two injection members, each having an injection port that couples to a source of fluid agent externally of the patient. The injection ports may be positioned with an outer region of blood flow along the abdominal aorta wall perfusing the two renal arteries. A flow isolation assembly may isolate flow of the injected agent within the outer region and into the renals. The injection members are delivered to the location in a first radially collapsed condition, and bifurcate across the aorta to inject into the spaced renal ostia. A delivery catheter for upstream interventions is used as a chassis to deliver a bilateral local renal injection assembly to the location within the abdominal aorta.

The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

The present invention discloses agents and methods for inducing osteoblastic cellular differentiation, as well as the use of such agents and method to treat patients to maintain bone mass, enhance bone formation and / or bone repair. Exemplary agents include oxysterols, alone or in combination with particular oxysterols, or other agents known to assist in bone formation. The invention further includes medicaments including oxysterols for the treatment of bone disorders, local injections of oxysterols or cells (206) and implants (202) having agents or cells (203) to facilitate bone repair.

Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces / prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and / or prevent normal and / or pathological scarring.

The invention relates to a preparation method and application of a fibrin glue composite recombinant human bone morphogenetic protein-2 (rhBMP-2) microsphere. The preparation method comprises the steps of: preparing a slow release microsphere with a proper particle diameter; and then constructing an rhBMP-2 / PLGA microsphere / fibrin glue composite material. The rhBMP-2 / PLGA microsphere fibrin glue composite material can be used through local injection, surgical trauma can be reduced, a healing process of bone fracture and nonunion is accelerated by continuously supplementing the local bone morphogenetic protein, thus the fibrin glue composite recombinant human bone morphogenetic protein-2 is a bone repair material with excellent degradability and osteogenic activity.

A compact, low profile splicing system for joining optical fibers produces durable, low transmission loss fusion splices. The system employs active optical techniques such as profile alignment or local injection and detection to achieve optimized alignment of the fibers prior to fusion. Light injected into one fiber is propagated across the interface to a second fiber. A detector senses the intensity of the injected light in the second fiber. After the relative position of the fibers is manipulated to maximize the transmitted intensity, the fibers are fusion spliced using an electric arc discharge. The accurate alignment achievable using the local injection and detection system to drive adaptive fiber positioning affords a method for reliably producing low loss splices. The present system is compact and low in profile, making it operable in cramped quarters with limited clearance to adjacent equipment and structures and with only a minimal amount of free fiber slack available. Simplicity of design and operation make the system rugged and enable accurate alignment and low loss fusion of fibers under adverse working conditions.

The invention discloses a joint lubricating material and a preparation method thereof. The material is covalent crosslinked O-carboxymethyl chitosan hydrogel, wherein the gelation time is 0.5-10min, the water content is higher than 70%, and the water retention rate is higher than 65%; and the material is prepared by carrying out gelation reaction between O-carboxymethyl chitosan of which the degree of deacetylation is greater than 25% and glutaric dialdehyde. The prepared covalent crosslinked O-carboxymethyl chitosan hydrogel has good biocompatibility, can serve as a joint lubricating agent, is suitable for local injection of joints, and can enable the joints to keep certain capacity and elastic properties within certain time so as to promote cartilage tissue repair.

A splicing system for joining polarization-maintaining, single mode optical fibers produces durable fusion splices that have low transmission loss and maintain mode integrity. The system employs active optical techniques such as profile alignment or local injection and detection to achieve optimized lateral alignment of the fibers prior to fusion. Azimuthal alignment is performed using a transverse, polarized light illumination and detection system. Each fiber is rotated azimuthally to determine a transverse intensity function. The transverse intensity functions of the respective fibers are cross-correlated to determine a relative orientation that matches the polarization axes of the fibers. After the relative position of the fibers is manipulated laterally, axially, and azimuthally, the fibers are fusion spliced using an electric arc discharge. The accurate alignment achievable using the transverse illumination mechanism to drive adaptive fiber positioning affords a method for reliably producing low loss, mode-matched splices. Simplicity of design and operation make the system rugged and enable accurate alignment and low loss fusion of fibers under adverse working conditions.

A slow release injection contains bioactive components, slow release adjuvants, a suspending agent and a dissolvant, wherein, the dissolvant is a common dissolvant or a special dissolvant containing the suspending agent. The slow release adjuvants are chosen from copolymer of polylactic acid, polyglycolic acid and hydroxyacetic acid, copolymer of ethylene vinyl acetate, polifeprosan, etc. The injection can be slowly released to the local focuses of tumors, inflammation and tuberculosis during the decomposition and absorption of the slow release adjuvants, therefore, the slow release adjuvants can not only extremely reduce general toxic reactions thereof but also keep the effective drug concentration at the chronic local focuses of tumors, etc. The suspending agent is chosen from sodium carboxymethyl cellulose, mannitol, and the like, and is used for suspending the active components or suspending the slow release particles or microspheres containing anticancer active components. The slow release injection has the advantages of good injectivity, seldom blockage, strong stability, infrequent demixing, and little general toxic reaction of local injection; furthermore, the slow release injection can selectively increase the drug concentration in local focuses, and enhance the curative effects of non-operative therapies such as radiotherapy, chemotherapy, and the like.